Who are lenalidomide, bortezomib and dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenalidomide-bortezomib-and-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

lenalidomide, bortezomib and dexamethasone — Competitive Intelligence Brief

lenalidomide, bortezomib and dexamethasone (lenalidomide, bortezomib and dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid. Area: Oncology.

phase 3 Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid Multiple targets: cereblon (lenalidomide), 20S proteasome (bortezomib), glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

lenalidomide, bortezomib and dexamethasone (lenalidomide, bortezomib and dexamethasone) — National Heart, Lung, and Blood Institute (NHLBI). This three-drug combination works by enhancing immune cell activity (lenalidomide), inhibiting proteasome function to trigger cancer cell death (bortezomib), and suppressing inflammation (dexamethasone) to treat multiple myeloma.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lenalidomide, bortezomib and dexamethasone TARGET	lenalidomide, bortezomib and dexamethasone	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid	Multiple targets: cereblon (lenalidomide), 20S proteasome (bortezomib), glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: immunomodulatory agent, proteasome inhibitor, and corticosteroid class)

National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lenalidomide, bortezomib and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-bortezomib-and-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab